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Report  
Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterize 
a Distinct Molecular Sub-Group of Medulloblastomas Associated with  
a Favorable Prognosis
AbStRACt
The accurate assessment of disease risk remains a major goal in children with medul‑
loblastoma. Activation of the canonical Wnt/Wingless (Wnt/Wg) signalling pathway 
occurs in up to 25% of cases and is associated with a favorable disease outcome. To 
explore the molecular pathogenesis of Wnt/Wg‑active medulloblastomas, and to inves‑
tigate any genetic basis for their observed clinical behavior, we assessed a series of 
primary medulloblastomas for evidence of Wnt/Wg pathway activation, alongside a 
genome‑wide analysis of associated copy‑number aberrations. Cases displaying evidence 
of Wnt/Wg activation (CTNNB1 mutation and/or β‑catenin nuclear stabilisation) were 
exclusively associated with a distinct genomic signature involving loss of an entire copy 
of chromosome 6 but few other aberrations (p < 0.001). In contrast, Wnt/Wg‑negative 
tumors coclustered into an unrelated sub‑group characterised by multiple established 
genomic defects common in medulloblastoma (losses of chromosomes 17p, 8, 10 and 
16; gains of chromosomes 7 and 17q). Further investigation of specific genetic defects 
in a larger independent cohort demonstrated that loss of chromosome 6 was exclusively 
observed in Wnt/Wg‑active tumors, but not in Wnt/Wg‑negative cases (8/13 vs. 
0/19; p = 0.0001), while pathway activation was independent of chromosome 17 
aberrations, the most common chromosomal alterations detected in medulloblastoma 
(p = 0.005). Wnt/Wg‑active tumors could not be distinguished on the basis of clinical 
or pathological disease features. Our data indicate that Wnt/Wg‑active tumors represent 
an independent molecular sub‑group of medulloblastomas characterised by a distinct 
pattern of genomic aberrations. These findings provide a strong biological basis to 
support (1) the idiosyncratic clinical behavior of Wnt/Wg‑active medulloblastomas, 
and (2) the development of  β‑catenin status as an independent marker for therapeutic 
stratification in this disease.
intRoDuCtion
The accurate assessment of disease risk remains a major goal in the clinical management 
of patients with medulloblastoma, the most common malignant brain tumor of childhood. 
Despite recent advances in overall survival rates (to ~70% at five years), variability in 
outcome exists within current therapeutic risk groups defined by clinical and histopatho-
logical indices, and contemporary adjuvant therapies are associated with significant adverse 
effects.1 The development of a robust schema for the accurate therapeutic stratification 
of medulloblastoma patients (i.e., intensive therapy for high-risk patients and reduced 
side-effects for low-risk cases), and the identification of biological markers to facilitate this, 
are therefore imperative.
Activation of the canonical Wnt/Wg signalling pathway is a feature of up to 25% of 
medulloblastomas. Pathway activation is mediated through the stabilisation and nuclear 
accumulation of β-catenin, a transcriptional activator, and is associated with activating 
mutations in its corresponding CTNNB1 gene in the majority (~60%) of instances.2-4 
In a recent study of 109 patients enrolled in the SIOP PNET3 clinical trial, we showed 
that Wnt/Wg pathway activation is an independent marker of favorable outcome in 
medulloblastoma. Five-year overall survival rates were significantly higher for β-catenin 
nucleopositive than nucleonegative medulloblastomas (92.3% vs. 65.3%), and all children 
with β-catenin nucleopositive medulloblastomas displaying clinical or histopathological 
adverse-risk features (metastatic disease or large cell/anaplastic morphology) were alive at 
least five years post-diagnosis.2
To explore the molecular pathogenesis of Wnt/Wg-active medulloblastomas, and to 
investigate any genetic basis for their observed favorable prognosis, we assessed a series of 
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primary medulloblastomas for evidence 
of Wnt/Wg pathway activation, alongside 
a genome-wide analysis of associated 
genomic copy-number aberrations.
MEthoDS
Two independent cohorts of primary 
medulloblastomas were assessed, compri-
sing 19 and 32 cases, respectively. Clinical 
details (age at diagnosis, sex, histopatholo-
gical sub-type) are summarized in Figures 1 
and 3. DNA was extracted using standard 
methods. Markers of Wnt/Wg pathway 
activation (β-catenin nuclear stabilisation; 
CTNNB1 and APC mutation status) were 
assessed as previously described.2
Genomic aberrations were assessed by 
ar-CGH using arrays of 2464 genomic 
clones (BAC or P1), spaced across the 
human genome at an average interval 
of 1.2Mb, and printed in triplicate 
(HumArray2.0). ar-CGH analysis, 
imaging and data processing were carried 
out by the Microarray Core at the 
UCSF Comprehensive Cancer Center, as 
described previously.5,6 Circular binary 
segmentation7 was performed on the 
ar-CGH data by the Biostatistics Core 
at UCSF Comprehensive Cancer Center, 
as described previously, and mergeLevels8 
applied to translate experimental intensity 
measurements into regions of equal copy 
number, and to identify regions of copy 
number aberration. MAD values for all 
samples were <0.2, and minimum and 
maximum criteria used in mergeLevels 
were 0.05 and 2, respectively. Clones falling  
within regions of either copy number gain 
(green) or loss (red) were selected for unsupervised hierarchical 
clustering. Cluster analysis was performed using the Spotfire Decision 
Site 8.2.1 software (Somerville, MA) as described previously.9
Chromosome 6 status was determined by PCR and fragment 
analysis-based assessment of nine polymorphic microsatellite markers 
spanning the entire chromosome, using methods and criteria 
previously described by Langdon et al.10 17p status (encompas-  
sing 17p loss ocurring either in isolation or as a consequence of 
isochromosome(17)q) was detected by fluorescence in situ hybridi-
zation (FISH) as described previously by Lamont et al.11
RESuLtS
An initial cohort of 19 primary medulloblastomas was assessed for 
evidence of Wnt/Wg pathway activation (β-catenin nuclear stabiliza-
tion; CTNNB1 or APC mutation), alongside a genome-wide analysis 
of associated genomic copy-number aberrations by array-comparative 
genomic hybridisation (ar-CGH). Predicted activating mutations 
affecting the GSK-3β phosphorylation domain of CTNNB1 were 
detected in 16% (3/19) of cases (D32Y (GAC�TAC), G34E  
(GGA�GAA) and S37F (TCT�TTT)), two of which were associated         
with strong combined cytoplasmic and nuclear immunoreactivity for       
β-catenin (Fig. 1; mutation data not shown). No further evidence of          
pathway activation was detected, with all remaining cases displaying 
cytoplasmic, nonnuclear β-catenin immunoreactivity. 
ar-CGH analysis of this cohort revealed a spectrum of genomic 
aberrations consistent in number and nature with previous studies 
in medulloblastoma (reviewed in Ellison et al., 2003). The mean 
number of independent aberrations detected per sample was 5.5 ± 
4.9 (± SD), with gains of chromosome 7 and 17q regions and losses 
of chromosme 8, 10p/q, 11p/q, 17p and 19q regions representing the 
most commonly affected regions (each in �20% of cases). A highly 
distinctive genomic profile was revealed for the three Wnt/Wg-active 
(i.e., CTNNB1-mutated) tumors; each case harbored a complete loss 
of one copy of chromosome 6, with few further detectable defects 
(no further alterations in two cases and two additional alterations in 
the remaining case) (Fig. 1).
To compare the genomic profiles of Wnt/Wg active medull-
oblastomas with our wider cohort, we performed an unsupervised 
hierarchical cluster analysis, which organised the full cohort into 
two major groups, A and B. A third cluster (C) compried an indivi-
dual sample with no detectable defects (Fig. 2). Tumors in clusters 
A (n = 5) and B (n = 13) were distinguished primarily by (1) the 
lower number of independent defects detected in group A cases 
Figure 1. Assessment of Wnt/Wg pathway activation and associated genomic aberrations medullobla‑
stomas. (A) β‑catenin IHC, showing examples of strong combined cytoplasmic and nuclear reactivity 
(A1) and cytoplasmic, nonnuclear staining (A2), in two classic medulloblastomas. (B) ar‑CGH data for 
three medulloblastoma samples which harbour CTNNB1 mutations. Results are shown in genome order 
for 2371 probes, representing the human autosomes. Note clear evidence of loss of an entire copy of 
chromosome 6 in all 3 cases, with few additional chromosomal abnormalities.
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[1.60 (±0.89) vs. 6.86 (±5.02); p = 0.02, Mann-Whitney test], and 
(2) their distinct patterns of genomic aberrations. Wnt/Wg activa-
tion characterized the major specific sub-cluster (A'; n = 3) within 
group A; alongside the significantly lower number of independent 
genomic defects detected in each of these cases, cluster A' cases were 
exclusively and significantly associated with CTNNB1 mutation (p = 
0.001), β-catenin nuclear immunopositivity (p = 0.018) and chro-
mosome 6 loss (p = 0.001; all Fisher�s exact test), with none of these       
features observed in the remainder of the cohort. In contrast, cluster 
B represented the majority of tumors tested and was characterised by 
multiple genomic aberrations, including characteristic medullobla-
stoma genomic defects (see above). Notably, none of these defects 
was detected in the Wnt/Wg (A') cluster. 
Chomosome 17 defects, the most common 
genomic defects observed in medullobla-
stoma, were exclusively observed in cluster 
B cases, but occurred independently of the 
Wnt/Wg (A') cluster (p = 0.021, Fisher�s 
exact test). The remaining characteristic 
medulloblastoma defects (gain of chromo-
some 7, regional losses of chromosomes 8, 
10 and 11) showed a trend towards exclu-
sion from the Wnt/Wg cluster, although 
results did not reach statistical significance 
in this limited cohort.
To expand and validate these findings, 
we next assessed the relationship between 
Wnt/Wg pathway status and specific 
chromosmal aberrations in a second 
larger independent group, derived from 
our previous study of Wnt/Wg activation 
in medulloblastomas from the PNET3 
cohort.2,11 Briefly, this cohort comprised 
13 Wnt/Wg-active tumors as determined 
by β-catenin nuclear immunoreactivity 
(of which 9 (69%) harbored CTNNB1 
mutations) and 19 Wnt/Wg-negative 
control cases. These cases were assessed 
for specific chromosomal defects (loss of 
chromosome 6 and 17p; Fig. 3), as their 
prior fixation in formalin precluded infor-
mative genome-wide ar-CGH analysis. In 
this wider cohort, loss of entire chromo-
some 6 was exclusively and significantly 
associated with Wnt/Wg-activation (p = 
0.0001, Fisher�s exact test). Chromosome    
6 loss was a feature of 62% (8/13) of 
β-catenin nucleopositive cases, inclu-
ding cases with (6/9) and without (2/4) 
CTNNB1 mutation. Again, Wnt/Wg 
activation occurred independently of 
chromosome 17p loss, which was only 
observed in Wnt/Wg-negative control 
cases (7/13 informative cases; p = 0.005, 
Fisher�s exact test).  
DiSCuSSion
Our data indicate strongly that 
Wnt/Wg pathway activation defines 
a distinct molecular sub-group of medulloblastomas, which 
harbor a characteristic genomic signature involving chro-
mosome 6 loss and few other detectable defects, and which 
appear to be independent of tumors containing common 
characteristic medulloblastoma defects, such as chromosome 17 
aberrations. Notably, Wnt/Wg cases could not be distinguished 
within either cohort on the basis of basic clinical or histopathological 
information (age at diagnosis, sex, histopathological sub-type; all p 
� 0.05), futher supporting the utility of Wnt/Wg activation as an 
independent biological marker for medulloblastoma. However, the 
relevance of Wnt/Wg activation in nodular/desmoplastic medull-
oblastomas and medulloblastomas from children aged under three 
Figure 2. Cluster analysis of genomic aberrations detected in medulloblastomas, and their relationship 
to Wnt/Wg pathway activation status. ar‑CGH clones falling within regions of either copy number gain         
(green) or loss (red) were selected for unsupervised hierarchical clustering as shown. Data are shown by 
chromosome, with major coclusters indicated (A, A‘, B and C). Wnt/Wg pathway status and the total 
number of independent regions of copy number aberration detected for each sample are also shown, 
alongside clinical descriptors (age in years; sex, male (M), female (F); histopathological sub‑type, classic 
(C), nodular/desmoplastic (ND), medulloblastoma with extensive nodularity (MB).
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years (ineligible for the PNET3 trial) remains undeter-
mined. Our findings are corroborated by the recent study 
of Thompson et al.,4 which reported characteristic gene 
expression patterns and genomic aberrations, including 
chromosome 6 loss, in five medulloblastomas harboring 
CTNNB1 mutations. The unique molecular pathogenesis 
of Wnt/Wg medulloblastomas provides a strong biological 
basis to support (1) their idiosyncratic clinical behavior, 
and (2) the development of  Wnt/Wg sub-group markers 
as independent indices for therapeutic stratification in 
this disease.
Whilst our data strongly support a unique genomic 
signature for Wnt/Wg medulloblastomas, more detailed 
analyses are now required to elucidate the molecular 
mechanisms underlying their pathogenesis and favorable 
response to therapy. In particular, further investigations 
involving larger cohorts and enhanced resolution mapping 
arrays are essential in the short-term, both to verify our 
findings and to identify further characteristic genomic 
events. An understanding of the contribution of chromo-
some 6 loss to Wnt/Wg tumor development may offer 
particular insights. Outstanding issues include (1) whether 
whole chromosome 6 loss is necessary, potentially invol-
ving a chromosome-wide reduction in “gene-dosage“, or 
whether specific critical genes are targeted for inactivation 
by smaller genetic or epigenetic events not revealed at the 
~1.4Mb mapping array resolution used in the present 
study, and (2) whether Wnt/Wg pathway activation and 
inactivation of genes on chromosome 6 cooperate directly 
in promoting medulloblastoma development. Moreover, 
the interplay between Wnt/Wg activation and additional 
genetic events could be complex; for instance, evidence 
of MYC amplification, a marker of poor prognosis 
in medulloblastoma, has been reported in a Wnt/Wg 
tumor.2,11 Finally, the distinct genomic signature of Wnt/   
Wg tumors may reflect a unique ontogeny. While strong  
evidence exists to support the development of a subset of 
medulloblastomas (~25%), which display activation of 
the SHH signalling pathway, from the external granule 
layer of the cerebellum,12 the developmental origins of 
other tumors are less clear. Gene expression data suggest 
that Wnt/Wg medulloblastomas and medulloblastomas 
displaying SHH activation are mutually exclusive,4 and 
studies to investigate the cerebellar precursor cells from    
which they originate should be highly informative.
In view of the favorable outcome observed for Wnt/
Wg medulloblastomas,2 Wnt/Wg status represents an 
attractive marker for the molecular stratification of favo-
rable-risk medulloblastoma patients. Three alternative 
markers, which exclusively identify Wnt/Wg tumors, 
have now been identified; (1) β-catenin nuclear immuno-
reactivity, (2) CTNNB1 mutation, and (3) chromosome 
6 loss. All of these features were amenable to assessment 
using standard technologies (IHC, PCR and iFISH) in 
formalin-fixed material, in the present study. β-catenin 
nuclear stabilisation defined 15/16 of the Wnt/Wg sub-group cases 
reported here (Figs. 2 and 3) and, of these, the Wnt/Wg sub-type 
was further corroborated in 13/15 cases by the presence of either 
a CTNNB1 mutation (11/15 cases) or chromosome 6 loss (10/15 
cases). Thus, the application of β-catenin IHC as a primary marker, 
in conjunction with confirmatory CTNNB1 mutation detection 
(PCR/sequencing) and assessment of chromosome 6 loss (by PCR 
or FISH-based methods), appears to offer a robust approach for the 
positive discrimination of Wnt/Wg sub-group medulloblastomas in 
diagnostic biopsies.
Figure 3. Wnt/Wg pathway activation, chromosome 6 loss and chromosome 17p 
status in an independent medulloblastoma cohort. Wnt/Wg pathway status and clinical     
features (age in years; sex, male (M), female (F); histopathological sub‑type, classic 
(C), large cell/anaplastic (LCA)) are shown for 32 medulloblastomas. Polymorphic 
markers on chromosome 6 were classified as either homozygous (dark grey boxes) or 
heterozygous (white boxes). Using this approach, regions of contiguous homozygos‑
ity encompassing ≥ 5 markers are significantly associated with loss of heterozygosity 
(i.e., allelic loss). Noninformative markers are represented by cross‑hatched boxes. A 
summary of chromosome 6 status determined for each sample is shown (dark grey 
boxes, allelic loss of entire chromosome 6; white boxes, no evidence of chromosome 6 
loss). 17p status was determined for 22 cases (dark grey box, 17p loss; white box, no               
17p loss; cross‑hatched box, data not available).
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Molecular (17p loss, amplification of the MYC or MYCN onco-
genes), clinical (metastatic and post-operative residual disease) and 
histopathological (large cell/anaplastic morphology) indices that 
predict a poor prognosis, have been identified in studies conducted 
in medulloblastoma clinical trials cohorts.11,13 Stratification schemes 
involving the combined use of multiple indices may thus offer 
attractive systems for the robust positive discrimination of poor, 
average and favorable risk cases.11 The interplay between Wnt/
Wg activation and other biological, clinical and histopathological 
markers of prognosis in medulloblastoma should now therefore be 
considered in prospective group-wide biological studies involving 
uniformly treated cohorts, with a view to (1) validating present 
findings, (2) defining optimal stratification systems, and (3) assessing 
the feasibility of biological testing in multi-centre studies, including 
appropriate quality control procedures, prior to assimilation into 
routine clinical practice.
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